CatalystFDA/Bio

ULTRAGENYX SHARES FALL AFTER PHASE 3 ASPIRE STUDY MISSES PRIMARY ENDPOINT - YAHOO

Phase 3 miss directly impacts ULTRAGENYX shares, triggering negative market reaction.

What changed

Phase 3 miss directly impacts ULTRAGENYX shares, triggering negative market reaction.

Why it matters

Phase 3 miss directly impacts ULTRAGENYX shares, triggering negative market reaction. — impact context not separately stored; see What changed.

Sources